Dechra, a global leader in veterinary specialty care, today shares the FDA approval of Emeprev™ (maropitant citrate) Injectable Solution, the first FDA-approved bioequivalent injectable solution to the most widely used antiemetic for dogs and cats.
BD a leading global medical technology company, announced the global commercial release of new configurations of cell analyzers featuring breakthrough spectral and real-time cell imaging technologies, enabling more labs in academia, pharma and biotech – across scales, needs and budgets – to advance discoveries in immunology, cancer immunotherapy and cell biology.
Citius Oncology, Inc. the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. announced the commercial launch of LYMPHIR™ (denileukin diftitox-cxdl). LYMPHIR is a novel IL-2 receptor-directed fusion protein approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory (r/r) Stage I–III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.
Centinel Spine®, LLC the leading global medical device company focused exclusively on treating cervical and lumbar spinal disease with the most complete and clinically-proven total disc replacement (TDR) technology platform in the world (prodisc®), announced a significant coverage advancement for lumbar TDR in Arizona.
AbbVie announced primary results from the pivotal Phase 3 ECLIPSE study, evaluating the safety, efficacy and tolerability of atogepant (60 mg) versus placebo for the acute treatment of migraine in adults (with or without aura).
Fresenius Kabi, part of the global healthcare company Fresenius, and a leading provider of essential medicines and medical technologies, announced it has introduced Dalbavancin for Injection (for single-dose regimen use only), which is indicated for the treatment of adult and pediatric patients with acute bacterial skin and skin structure infections caused by designated susceptible strains of Gram-positive microorganisms.
Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that precisely target disease pathology, announced the appointment of Dennis Dean, Ph.D., as Executive Vice President and Head of Non-Clinical Development.
Eisai Co., Ltd. and Biogen Inc. announced that lecanemab-irmb subcutaneous injection (U.S. brand name: LEQEMBI® IQLIKTM) is now available in the U.S. as a maintenance dosing regimen for the treatment of Alzheimer's disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD). After 18 months of LEQEMBI (lecanemab-irmb) intravenous (IV) treatment at 10 mg/kg every two weeks, patients may either continue IV infusions at 10 mg/kg once every four weeks or start the new weekly 360 mg subcutaneous injection using the LEQEMBI IQLIK autoinjector.
Veloxity Labs, a bioanalytical CRO built for programs that need speed with purpose, announced the acquisition of the ZenoTOF 8600 system from SCIEX, a global leader in life science analytical technologies. Veloxity is the first bioanalytical CRO in the United States to acquire this new accurate mass spectrometer, with delivery expected later this year and installation/qualification starting January of 2026.
Merz Aesthetics, the world’s largest dedicated medical aesthetics business, announced today the launch of a new syringe for its category-leading hyaluronic acid (HA) brand BELOTERO®. The new syringe is ergonomically engineered to elevate the treatment experience, offering greater precision, comfort, and ease of use. The new syringe will launch first in Europe and then will expand to markets worldwide.